Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr:262-263:57-63.
doi: 10.1016/j.cancergen.2022.01.002. Epub 2022 Jan 19.

The clinical aspect of NTRK-fusions in pediatric papillary thyroid cancer

Julio C Ricarte-Filho  1 , Stephen Halada  1 , Alison O'Neill  1 , Victoria Casado-Medrano  1 , Theodore W Laetsch  2 , Aime T Franco  3 , Andrew J Bauer  4
Affiliations
Review

The clinical aspect of NTRK-fusions in pediatric papillary thyroid cancer

Julio C Ricarte-Filho et al. Cancer Genet. 2022 Apr.

Abstract

Although adult and pediatric papillary thyroid cancer (PTC) share similar oncogenic drivers, they differ in the pathological features and outcomes of the disease. In adults with PTC, the most frequent genetic alterations are mutually exclusive point mutations in BRAFV600E or the RAS family with BRAFV600E commonly associated with invasive disease and decreased response to radioiodine therapy. In pediatric PTC, fusion oncogenes involving chromosomal translocations in tyrosine kinase (TK) receptors, most commonly RET and NTRK, are often found in patients with lateral neck and distant metastases. This brief report reviews clinical data from a single-institute's cohort of NTRK-driven pediatric PTC cases with an updated review of the literature and comparison to adult NTRK-driven PTC.

Keywords: Adult thyroid cancer; NTRK fusion; Oncogene; Pediatric.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Clinical characteristics of pediatric and adult patients harboring NTRK fusion oncogenes.
NTRK1 and NTRK3 fusions stratified by pediatric (CHOP) and adult PTC (TCGA). Clinicopathological characteristics includes sex, age, histology, tumor (T) status, lymph node (N) metastasis status, distant metastasis status (M), radioactive iodine (RAI) therapy and remission status 1 year after initial treatment. *Adult case harboring IRF2BP2-NTRK1 fusion also has a CCDC6-RET fusion.
See this image and copyright information in PMC

References

    1. Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti JM, Dinauer CA, Hamilton J, Hay ID, Luster M, Parisi MT, Rachmiel M, Thompson GB, Yamashita S, American Thyroid Association Guidelines Task F. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2015;25:716–59. - PMC - PubMed
    1. Scott AR, Stoltzfus KC, Tchelebi LT, Trifiletti DM, Lehrer EJ, Rao P, Bleyer A, Zaorsky NG. Trends in Cancer Incidence in US Adolescents and Young Adults, 1973–2015. JAMA Netw Open 2020;3:e2027738. - PMC - PubMed
    1. Hogan AR, Zhuge Y, Perez EA, Koniaris LG, Lew JI, Sola JE. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res 2009;156:167–72. - PubMed
    1. Al-Qurayshi Z, Hauch A, Srivastav S, Aslam R, Friedlander P, Kandil E. A National Perspective of the Risk, Presentation, and Outcomes of Pediatric Thyroid Cancer. JAMA Otolaryngol Head Neck Surg 2016;142:472–8. - PubMed
    1. Niedziela M Thyroid nodules. Best Pract Res Clin Endocrinol Metab 2014;28:245–77. - PubMed

Publication types

Substances